Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

KeChow Approved to Launch Tunlametinib for Melanoma Patients in China

publication date: Mar 18, 2024

Shanghai KeChow Pharma was approved to market tunlametinib in China to treat patients with NRAS mutated advanced melanoma who were previously treated with PD-1/PD-L1. Tunlametinib, KeChow’s lead candidate, is a small molecule inhibitor of Mitogen-activated protein kinase (MEK). KeChow believes its candidate does a better job of inhibiting targets and improving pharmacokinetics than already approved MEK inhibitors. The company, which owns global rights to tunlametinib, plans to develop the drug in China as a monotherapy and in combination with other standard of care therapies to treat additional cancers. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital